Basic Clarithromycin Information

• INN (International Nonproprietary Name): Clarithromycin.
• Brand Names Available In Australia: Klacid and Clarithromycin Sandoz are listed in the product reference for Australia.
• ATC Code: J01FA09.
• Forms & Dosages: Film-coated tablets 250 mg and 500 mg; extended-release 500 mg tablets; powder/granules for oral suspension 125 mg/5 mL and 250 mg/5 mL; paediatric suspensions 125 mg/5 mL and 250 mg/5 mL.
• Manufacturers In Australia: Branded and generic supplies in Australia include Klacid (Abbott/AbbVie, Pfizer) and Clarithromycin Sandoz; global manufacturers supplying the Australian market include Abbott, Sandoz, KRKA and others.
• Registration Status In Australia: TGA registered.
• OTC / Rx Classification: Prescription-only (Rx).

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Clinicians and pharmacists worry about rising macrolide resistance in community respiratory isolates and Helicobacter pylori isolates.

Australian state laboratory surveillance and published summaries from 2022–24 mirror international trends showing falling clarithromycin susceptibility for H. pylori in many regions.

Randomised trials still show clarithromycin-based regimens remain effective where the infecting pathogen is susceptible.

In H. pylori treatment trials, clarithromycin triple therapy now performs poorly in areas with high clarithromycin resistance unless local susceptibility testing guides therapy.

Trials of skin and soft-tissue infections continue to support clarithromycin for certain presentations when alternatives are unsuitable.

Practical stewardship messages from recent literature favour susceptibility-guided prescribing or switching to non-macrolide options where resistance is common.

Main Outcomes

H. pylori eradication rates with clarithromycin triple therapy are reduced in regions with increased clarithromycin resistance.

When susceptibility is confirmed, clarithromycin 500 mg twice daily as part of a combination regimen achieves acceptable cure rates in line with historical data.

For community respiratory infections and some skin infections, clarithromycin offers good tissue penetration and clinical improvement when pathogens are sensitive.

Extended-release and standard 500 mg dosing maintain convenient regimens, but twice-daily schedules for standard tablets can affect adherence compared with once-daily azithromycin.

Safety Observations (TGA Reports)

Regulatory safety summaries emphasise the known risk of clinically significant CYP3A4 drug interactions with clarithromycin.

TGA product information lists contraindicated combinations and cautions around QT prolongation and hepatic adverse events.

Post-market surveillance reports commonly note gastrointestinal adverse effects and reversible elevation of liver enzymes.

International agencies and TGA reminders reinforce contraindications such as concomitant cisapride, pimozide and ergot derivatives.

Clinical Mechanism Of Action

Layman’s Explanation

Patients often ask how clarithromycin works and why it sometimes causes a metallic taste.

Clarithromycin is a macrolide antibiotic that stops bacteria making the proteins they need to grow.

The drug slows bacterial growth so the immune system can clear the infection more easily.

It is generally described as bacteriostatic, though it can be bactericidal at higher concentrations for particular bacteria.

Scientific Breakdown

Clarithromycin binds to the bacterial 50S ribosomal subunit near the peptidyl-transferase centre and blocks peptide translocation.

This binding causes ribosomal stalling and prevents protein elongation in susceptible bacteria.

Common resistance mechanisms include methylation of the ribosomal binding site (erm genes) and active efflux pumps (mef genes) that reduce intracellular clarithromycin concentrations.

The drug is well absorbed from oral tablets and suspensions and shows good penetration into respiratory tissues.

Hepatic metabolism by CYP3A4 produces an active metabolite, 14-hydroxyclarithromycin, which contributes to clinical activity and interaction risk.

Because of CYP3A4 metabolism, dose scheduling and interaction checks are important in primary care and pharmacy counselling.

Scope Of Approved & Off-Label Use

Australian Approvals (TGA-Listed, PBS Inclusion)

Clarithromycin is TGA registered in Australia and appears under brand and generic names such as Klacid and Clarithromycin Sandoz.

Available dosage forms include clarithromycin 250 mg tablets, clarithromycin 500 mg tablets and paediatric clarithromycin oral suspension in 125 mg/5 mL and 250 mg/5 mL strengths.

Classification is prescription-only, and PBS listing is indication specific and varies by pack and strength.

Prescribers should check PBS criteria and authority requirements to determine subsidy eligibility for respiratory, skin and H. pylori regimens.

Notable Off-Label Trends In Australian Practice

Off-label uses recorded in Australian practice include treatment of atypical mycobacterial infections and specific prophylactic indications in ENT and dental settings.

Clarithromycin is also used in some H. pylori combination regimens where local susceptibility testing supports its use.

Prescribers increasingly document indications and consider stewardship when choosing macrolide therapy.

Pharmacists play a key role verifying PBS authority, counselling on clarithromycin dosing and interactions, and advising prescribers when contraindications are present.

Dosage Strategy

General Dosing

Standard adult dosing commonly used in Australia is 250–500 mg every 12 hours.

Extended-release clarithromycin 500 mg once-daily formulations are available for convenience in some markets.

Paediatric dosing for oral suspension is weight based at 7.5 mg/kg twice daily with a maximum single dose of 500 mg.

Treatment durations for respiratory infections typically range from 5 to 14 days depending on indication and clinical response.

Condition-Specific Dosing (PBS Recommendations)

For H. pylori eradication clarithromycin is commonly given 500 mg twice daily as part of combination therapy for 7–14 days.

Skin and soft-tissue infections frequently use 250–500 mg every 12 hours for 5–10 days depending on severity.

For mycobacterial infections clarithromycin dosing is often 500 mg twice daily but may vary with specialist guidance.

Renal impairment with creatinine clearance below 30 mL/min usually requires a 50% dose reduction.

Extended-release formulations should be avoided in severe hepatic impairment.

Pharmacists should confirm pack sizes align with the PBS authority and advise on missed-dose guidance: take as soon as remembered unless the next dose is near; do not double doses.

Safety Protocols

Contraindications (Australian Guidelines)

Absolute contraindications include known hypersensitivity to macrolides and prior cholestatic jaundice or hepatic dysfunction linked to clarithromycin.

Concomitant use with strong CYP3A4-interacting drugs such as cisapride, pimozide and ergot derivatives is contraindicated.

Relative cautions include significant hepatic or renal impairment and a history of QT prolongation or arrhythmias.

Pregnancy and breastfeeding require specialist consideration and consultation with current guidelines.

Adverse Effects (Post-Market Pharmacovigilance)

Common adverse effects reported after marketing include nausea, diarrhoea, abdominal pain and headache.

Metallic taste and transient reversible elevations in liver enzymes are also commonly cited.

Pharmacovigilance highlights the importance of checking for CYP3A4-mediated interactions and monitoring for QT prolongation risk.

Pharmacists should counsel patients on warning signs of liver dysfunction and advise immediate medical review for severe reactions.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

There are no major food restrictions for clarithromycin but tablets should be taken consistently with or without food as per product labelling.

Alcohol may worsen gastrointestinal side effects and is best limited while taking clarithromycin.

High coffee intake common in Australia does not significantly affect clarithromycin pharmacokinetics.

Drug Combinations To Avoid (TGA Safety Alerts)

The most clinically significant interactions arise from CYP3A4 inhibition and from additive QT prolongation.

Avoid concomitant simvastatin and lovastatin where possible because clarithromycin can increase statin concentrations via CYP3A4 inhibition.

Avoid cisapride and pimozide entirely as these are absolute contraindications with clarithromycin.

Exercise caution with some benzodiazepines, antiarrhythmics and ergot derivatives and consult prescribers for safe alternatives.

Pharmacies should use real-time interaction checks and recommend alternative antibiotics such as doxycycline or azithromycin when interaction risk is significant.

Patient Experience Analysis

Australian Survey Data

Australian surveys through mid-2024 show patients generally find clarithromycin effective for respiratory and skin infections.

Common patient complaints include metallic taste and gastrointestinal upset such as nausea or diarrhoea.

Adherence is sometimes an issue with twice-daily regimens compared with once-daily alternatives like azithromycin.

Pharmacists report that cost sensitivity leads many patients to request generic clarithromycin Sandoz or PBS-subsidised packs.

Forum And Pharmacy Trends

Online forums commonly echo the clinical feedback: quick symptomatic improvement but complaints about taste disturbance.

Pharmacy counselling trends across major chains and independents show frequent advice on drug interactions and PBS entitlements.

Rural patients rely heavily on local pharmacists for dosing checks and interaction screening, with telehealth e-scripts improving access but sometimes complicating continuity of care.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Clarithromycin products are stocked across major Australian chains and independent pharmacies under brand and generic labels.

Pack sizes commonly sold include boxes of 10, 14 and 20 tablets aligned to typical treatment durations.

Patients often select generic clarithromycin Sandoz or branded Klacid 250 mg or Klacid 500 mg depending on price and PBS subsidy.

Online Pharmacy Growth And Telehealth E-Scripts

Telehealth and online pharmacies have increased the use of e-scripts and remote dispensing across Australia.

Improved access via online ordering helps people in remote areas but requires careful medication reconciliation to avoid interaction risks.

For convenience, discreet delivery options are available with typical delivery times ranging from 5 to 14 days depending on location.

PBS Vs Private Cost Comparisons

When PBS criteria are satisfied, patients commonly pay the PBS co-payment rather than the full private price for clarithromycin packs.

Private costs vary by brand and pharmacy with discount chains often advertising lower out-of-pocket prices for clarithromycin 250 mg and clarithromycin 500 mg tablets.

Pharmacists should proactively check PBS eligibility and offer generic alternatives where appropriate to reduce cost for patients.

Alternative Options

Comparison Of PBS And Non-PBS Options

When clarithromycin is unsuitable, azithromycin, doxycycline and amoxicillin are common alternatives depending on the infection.

Azithromycin offers once-daily or shorter-course options though macrolide resistance remains a shared concern.

Doxycycline is an effective alternative for many respiratory and skin infections and has minimal CYP3A4 interactions.

For H. pylori, bismuth quadruple regimens and levofloxacin-based salvage therapies are recommended where clarithromycin resistance is high.

Pros And Cons Checklist

• Clarithromycin: Good tissue penetration and established role in H. pylori where susceptibility is known, but CYP3A4 interactions and rising resistance are drawbacks.
• Azithromycin: Convenient dosing and good compliance, but shares macrolide resistance issues and has a long half-life.
• Doxycycline: Broad activity and minimal CYP3A4 interactions, but causes photosensitivity and is contraindicated in young children and pregnancy.

Regulatory Status

TGA Approval Framework

Clarithromycin products such as Klacid and Clarithromycin Sandoz are registered with the TGA for prescription use in Australia.

TGA registration confirms assessed safety, efficacy and manufacturing quality and the product information includes dosing, contraindications and storage instructions.

Post-market obligations include adverse event reporting to the TGA by sponsors and healthcare professionals.

PBS Subsidy Process

PBS listing for clarithromycin is indication-specific and often requires prescriber documentation or authority approval to obtain a subsidy.

Prescribers must select the correct PBS item number and pack size consistent with recommended duration to secure subsidy.

Pharmacists should verify documentation for authority prescriptions and retain records as required by PBS procedures.

Consolidated FAQ

Q: Can I get clarithromycin on the PBS?

A: PBS subsidy depends on the indication and authority criteria and pharmacies can check PBS item numbers and prescriber authority for eligibility.

Q: Is clarithromycin safe with my statin?

A: Clarithromycin inhibits CYP3A4 and may interact with simvastatin or lovastatin, so clinicians often switch statins or advise holding them during therapy.

Q: Can children take clarithromycin?

A: Yes, paediatric suspensions are available and dosing is weight based at 7.5 mg/kg twice daily with a single dose limit of 500 mg.

Q: What if I miss a dose?

A: Take the missed dose as soon as remembered unless the next dose is near, and do not double the dose.

Q: How should I store clarithromycin?

A: Store tablets below 25°C in a dry place and reconstituted suspension at or below room temperature for up to 14 days; do not freeze.

Visual Guide

The following visuals are designed to help pharmacy teams and patients at a glance.

Infographic 1: PBS Pricing — show PBS vs private cost for common 10- and 14-tablet packs, include brand and generic price ranges across major chains and highlight PBS eligibility cues.

Infographic 2: Pharmacy Distribution Map — urban versus rural stock reliability, telehealth e-script uptake rates, typical pack sizes such as clarithromycin 250 mg and clarithromycin 500 mg tablets and suspensions.

Infographic 3: Interaction Flowchart — a quick pharmacist check from current medicines to CYP3A4 substrate assessment and QT risk, then recommend alternatives or consult the prescriber.

Data sources for visuals should include TGA registration information, common brands such as Klacid and Clarithromycin Sandoz, and supplier names like Abbott, Sandoz and KRKA.

Storage & Transport

Household Storage Under Australian Climate

Store clarithromycin tablets below 25°C in a dry place and protect them from light and moisture, particularly during hot Australian summers.

Advise patients not to leave medicines in cars or in direct sunlight where temperatures can exceed recommended storage limits.

Reconstituted paediatric suspension should be used within 14 days and stored at or below room temperature; suspensions must never be frozen.

Cold-Chain Logistics For Pharmacies

Pharmacies should store stock away from direct sunlight and rapid temperature changes and rotate batches using expiry dates.

During transport to remote or rural pharmacies or for courier delivery, temperature-controlled packaging is advised if ambient temperatures risk exceeding stability ranges.

Wholesalers supplying clarithromycin stock may include Abbott, Sandoz and KRKA, and regional shortages can lead to therapeutic substitution when necessary.

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Use a patient-centred approach: confirm the indication, review concomitant medicines for CYP3A4 interactions and QT risk, and check PBS status before supply.

Explain dosing clearly for tablets and suspension and provide measuring devices for paediatrics when dispensing clarithromycin oral suspension.

Highlight likely side effects such as gastrointestinal upset and metallic taste and advise when to seek medical attention for severe reactions.

Document counselling and escalate to the prescriber if significant interactions or contraindications are identified.

National Health Authority Recommendations

Align counselling and prescribing with TGA product information and local therapeutic guidelines, including antimicrobial stewardship policies.

Prefer susceptibility-guided use for H. pylori and avoid prescribing macrolides for presumed viral infections to limit resistance development.

Report suspected serious adverse events to the TGA to support national safety monitoring.

Delivery Across Australia

Final Practical Notes

When advising patients, check for common brands such as Klacid and Clarithromycin Sandoz and prescribe or dispense the strength that matches PBS authority and treatment duration.

Use interaction-checking systems to screen for CYP3A4 substrates such as simvastatin and for QT-prolonging medicines before supply.

For suspected H. pylori, recommend local susceptibility testing where available or choose a bismuth quadruple regimen if clarithromycin resistance is likely.

Pharmacists should remind patients to complete the full course of clarithromycin tablets or suspension even when symptoms improve.

Order verification and medication reconciliation are essential for safe telehealth e-script dispensing, and discreet delivery across Australia typically takes 5–14 days depending on location.